Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Tavotek Biotherapeutics

Request full access

Biopharmaceutical innovations targeting cancer and debilitating diseases with advanced monoclonal antibodies and multi-specific biologics

Lower Gwynedd Township, United StatesFounded 2019Biotech & Life Sciences

About Tavotek Biotherapeutics

Tavotek Biotherapeutics is a biotech startup that operates in the field of cancer treatment. The company is primarily focused on the development of innovative therapies for solid tumors, a type of cancer that begins in the solid organs such as the lungs, colon, or breast. Tavotek's main product is TAVO412, a multispecific biologic, which is currently in the first phase of human clinical trials. A multispecific biologic is a type of drug that can target multiple parts of a cancer cell at once, potentially making it more effective at stopping the disease.

The company also offers a range of platforms that support the development of these treatments. TavoSELECT™ is a library of antibodies or biomolecules that can target different types of proteins, including those that are hard to reach because they are protected by the blood-brain barrier. TavoPRECISE™ is a platform for developing monoclonal antibodies and multispecific biologics, which are types of drugs that can target specific cells. TavoELITE™ is a novel platform that targets intracellular, or inside the cell, targets for the treatment of cancer and other diseases.

Tavotek Biotherapeutics serves a global market, with operations in both the United States and China. The company's business model is based on the research, development, and eventual commercialization of its cancer treatments. Its revenue will primarily come from the sales of these treatments once they have been approved for use.

In summary, Tavotek Biotherapeutics is a promising biotech startup that is developing innovative cancer treatments. Its multispecific biologics and targeted platforms could potentially revolutionize the way we treat solid tumors and other diseases.

Source: Dealroom company data

At a glance

Status
Operational
Employees
9
Open positions
None listed
Dealroom signal
58.4/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Client focus
B2B

Funding history

3 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES BOther financing Nov 2021 $35M $140M CS Capital · Fontus Capital ↗
SERIES AOther financing Mar 2021 $20M $80M Oriza Holdings · New Alliance Capital · CTS Capital Advisors · Ming Bioventures —
Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

Tavotek Biotherapeutics website traffic

Latest recorded traffic for Tavotek Biotherapeutics is 100 monthly website visits, down 95.5% over the last three months. Tavotek Biotherapeutics's team declined 25% over the past year.

Latest monthly visits100 3-month web change-95.5% 1-year team growth-25%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Tavotek Biotherapeutics in the Lower Gwynedd Township ecosystem

Live from Dealroom

The Tavotek Biotherapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

11 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A11 investors entered at this stage

  • Apricot Capital
  • Yuansheng BioVenture
  • Oriza Holdings
  • New Alliance Capital
  • CTS Capital Advisors
  • Ming Bioventures
  • Lanhu Capital
  • GF Xinde Investment
  • YuanBio Venture Capital
  • CS Capital
  • Fontus Capital
Team profiled 3 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇨🇳 China50%
🇺🇸 United States50%
2 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Tavotek Biotherapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Tavotek Biotherapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.